FOXO4-DRI 14 mg

Key facts

FOXO4-DRI 14 mg is a lyophilized research peptide supplied by PrimeGen Co. (formerly PrimeGen Labs) for laboratory research use only. D-retro-inverso peptide referenced in p53 interaction and senescent-cell research. Each lot is RP-HPLC assayed against a release specification of ≥ 98%, with the measured value published on that lot’s certificate of analysis. It is not a drug, supplement, or cosmetic and is not for human or veterinary use.

Compound:: FOXO4-DRI 14 mg
Strength:: 14 mg
Purity (RP-HPLC):: ≥ 98% by RP-HPLC (release specification)
Form:: Lyophilized powder, sealed vial
Verification:: Third-party HPLC & MS
Price:: $194.00 USD
Storage:: -20 °C sealed . 2-8 °C after reconstitution
Ships from:: United States
Shipping:: United States only . 10-12 business days
Certificate of analysis:: Available digitally on request
Intended use:: Laboratory research use only
Stock status:: Low stock . few lots left

Laboratory specifications

Purity (RP-HPLC): ≥ 98% by RP-HPLC (release specification)
Molecular weight: ~5194 g/mol
CAS number: Not assigned
Form: Lyophilized powder
Appearance: White to off-white lyophilized powder or cake, free of visible particulates.
Solubility: Sterile or bacteriostatic water; DMSO for hydrophobic sequences
Endotoxin: < 0.25 EU/mg
Fill weight: 14 mg
Storage temperature: -20 °C sealed . 2-8 °C after reconstitution
Shelf life: 36 months at -20 °C from the manufacture date
Reconstitution: Add diluent slowly down the vial wall; do not shake or vortex
Synthesis: Solid-phase (SPPS)
Identity: ESI-MS confirmed
Residual solvent: < 0.5%
Closure: Crimped aluminium / butyl stopper
Distributed by: PrimeGen Co.

Storage & handling

Long-term

-20 °C, sealed, desiccated
In transit

Ambient stable up to 21 days
After reconstitution

2-8 °C, use within 21 days
Light exposure

Protect from direct light

Certificate of analysis

HPLC + MS report issued by an independent laboratory. The released PDF is available on request.

COA date: On request
Testing laboratory: Independent ISO lab
Purity: ≥ 98% by RP-HPLC (release specification)
Testing method: RP-HPLC + ESI-MS
Batch status: Released – report on request

Certificate of analysis: testing in progressThis compound is pending independent laboratory verification. The certificate is published upon completion of testing, and batch documentation is available upon release.Ask about testing statusAll certificates

Scientific overview

Research summary: D-retro-inverso peptide referenced in p53 interaction and senescent-cell research.

FOXO4-DRI is a retro-inverso peptide built from D-amino acids in reversed sequence order, engineered to mimic the FOXO4 interaction surface while resisting proteolysis. It is a standard tool compound in senolytic research.

Mechanism of action

Designed to interfere with the FOXO4-p53 protein-protein interaction that sequesters p53 in the nucleus of senescent cells. Disruption is reported to permit p53 mitochondrial translocation and selective apoptosis of senescent, but not proliferating, cells in culture.

Areas of scientific investigation

Senolytic screening and senescence-associated beta-galactosidase assays
FOXO4-p53 protein-protein interaction studies
Retro-inverso peptide design chemistry
Cellular ageing models

Listed fields describe where this sequence appears in published in vitro and preclinical literature. They are not indications, applications, or claims of effect.

Laboratory handling

Reconstitution

Supplied lyophilized; typically reconstituted in sterile water or PBS. As a D-amino-acid construct it is markedly protease-resistant, which simplifies long-incubation culture work.

Stability

As a sealed lyophilized powder the material is stable for extended periods at -20 °C when kept desiccated and protected from light. Once in solution, stability shortens considerably: aqueous stocks are normally held at 2-8 °C for short term work or aliquoted and frozen for longer storage. Repeated freeze-thaw cycling is the most common cause of measurable potency loss.

Packaging

Single sequence per vial, sealed under inert gas in USP Type I borosilicate glass with a butyl rubber stopper and crimped aluminium overseal. Each vial carries a printed PrimeGen label with product name, strength, lot number, manufacture and retest dates, storage temperature and a QR code linking to the lot record. Vials ship in a rigid foam insert inside a protective mailer at ambient temperature.

Research use only

For laboratory research purposes only. Not intended for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Purchasers are responsible for complying with all applicable laws and regulations.

FOXO4-DRI 14 mg – laboratory research dossier

This dossier collects everything a laboratory typically needs before requisitioning FOXO4-DRI at the 14 mg presentation: how the sequence is characterised in published literature, how the material is assayed and released, how it should be stored and reconstituted, and where it sits inside the wider specialty research catalogue. Every unit is supplied as a sealed lyophilized powder released to a specification of ≥ 98% by RP-HPLC, with the measured value for each lot recorded on that lot’s certificate of analysis. It is sold exclusively for laboratory research use. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use.

Scientific background

D-retro-inverso peptide referenced in p53 interaction and senescent-cell research. Investigators most often encounter this sequence in senolytic screening and senescence-associated beta-galactosidase assays and in foxo4-p53 protein-protein interaction studies, which is why the 14 mg vial is the format we release most frequently – it gives enough material for a full dose-response series at typical assay concentrations without leaving a large reconstituted surplus to store. This compound is catalogued at 2 strengths (10 mg, 14 mg), so a study can be scaled without changing lot chemistry.

Mechanism of action in published work

Descriptions above summarise observations reported in peer reviewed in vitro and animal literature. They describe what has been measured in model systems and are not claims of effect, indications, or guidance for use in humans or animals. Laboratories designing new work should return to the primary literature for concentration ranges, vehicle selection and control design, because reported effects in this class are strongly assay dependent.

Research applications

Published work involving FOXO4-DRI clusters into a small number of recurring experimental settings:

Senolytic screening and senescence-associated beta-galactosidase assays
FOXO4-p53 protein-protein interaction studies
Retro-inverso peptide design chemistry
Cellular ageing models

Because these are in vitro and preclinical contexts, the practical requirement on the material itself is consistency: a known mass of a single sequence, a stated purity, and a lot record that can be cited in a methods section. That is what the 14 mg vial and its accompanying certificate of analysis are designed to provide.

Analytical identity and specification

Compound: FOXO4-DRI
Presentation: 14 mg lyophilized powder, single sequence per vial
Release specification: ≥ 98% by RP-HPLC (release specification) – measured value on the lot certificate
Molecular weight: ~5194 g/mol
Appearance: White to off-white lyophilized powder or cake, free of visible particulates.
Unit price: $194.00 per vial

Purity, quality control and the certificate of analysis

Each FOXO4-DRI lot is assayed in house by reverse-phase HPLC and then re-tested by an independent analytical laboratory using HPLC alongside mass spectrometry for identity confirmation. The HPLC trace establishes the chromatographic purity figure recorded for the lot, which is released against a specification of ≥ 98% and reported on that lot’s certificate of analysis rather than quoted here as a fixed number – while the mass spectrometry step confirms that the observed molecular ion matches the expected mass for the sequence rather than a truncated or deletion analogue.

Certificates are issued digitally rather than enclosed in the shipment, which keeps the document versioned and retrievable long after the vial is consumed. You can view or request the current report from the certificates library, and the underlying chromatograms and spectra can be requested through laboratory support. Our full release criteria are documented on the quality control and laboratory standards pages.

Storage, reconstitution and stability

Storage. Sealed 14 mg vials are held desiccated and protected from light. Short holding periods at 2-8 °C are routine; for longer storage the lyophilized cake is kept at -20 °C. Allow the vial to equilibrate to room temperature before breaking the seal so that atmospheric moisture does not condense onto the powder.

Reconstitution. Supplied lyophilized; typically reconstituted in sterile water or PBS. As a D-amino-acid construct it is markedly protease-resistant, which simplifies long-incubation culture work.

Stability. As a sealed lyophilized powder the material is stable for extended periods at -20 °C when kept desiccated and protected from light. Once in solution, stability shortens considerably: aqueous stocks are normally held at 2-8 °C for short term work or aliquoted and frozen for longer storage. Repeated freeze-thaw cycling is the most common cause of measurable potency loss.

Handling. Work with the reconstituted solution under standard laboratory containment, record the reconstitution volume and date against the lot, and label aliquots with the resulting concentration. Volumes and concentrations are set by your own protocol; nothing on this page is a dosing instruction.

Experimental design considerations

The most common source of irreproducibility with lyophilized peptides is not the sequence itself but the arithmetic around it. A 14 mg vial contains a nominal peptide mass; the actual peptide content of any lyophilized cake also reflects counter-ion and residual moisture content, so laboratories reporting exact molar concentrations should either use the net peptide content figure from the lot certificate or determine content independently by amino acid analysis or quantitative UV. Using the published average mass of ~5194 g/mol, a full 14 mg vial reconstituted in 1 mL of diluent gives a convenient round stock concentration for serial dilution.

Three practical points recur in method sections for this class of material:

Vehicle matters. Record the diluent, its preservative content and its pH alongside the concentration. Bacteriostatic and sterile water are not interchangeable in every assay, and benzyl alcohol can interfere with sensitive cell based readouts.
Adsorption is real. At low working concentrations, peptides adsorb to polypropylene and glass. Low-bind labware or a carrier protein in the dilution buffer keeps the delivered concentration close to the nominal one.
Cite the lot. Because purity, counter-ion and net content vary between syntheses, methods sections should name the supplier lot for FOXO4-DRI so a later replication can be matched to the same analytical record.

Where a study spans several weeks, aliquoting the reconstituted stock immediately and freezing single-use volumes avoids the freeze-thaw cycling that accounts for most of the potency drift observed in longitudinal work.

Choosing the right presentation

FOXO4-DRI is released at 10 mg, 14 mg. Larger presentations lower the cost per milligram but commit a laboratory to using or storing more reconstituted material; smaller vials suit pilot work, method development and screening plates where a single stock is consumed quickly. The 14 mg vial listed on this page is priced at $194.00. Whatever presentation you select, the underlying material comes from the same synthesis and release programme, so switching strength does not change the analytical profile.

Orders ship from our facility in Chase City, Virginia, within the United States only, and every shipment carries the research use restriction on the outer documentation. Vials travel at ambient temperature in a rigid insert; lyophilized peptide is stable for the transit window, and the material should be moved to its long term storage temperature on arrival. Research materials are non returnable once dispatched.

Quality programme and laboratory support

Every FOXO4-DRI release passes through the same programme: synthesis against a defined sequence, in-house RP-HPLC purity assay, independent third party HPLC and mass spectrometry confirmation, visual inspection of the lyophilized cake, and a documented fill and seal step under inert gas in USP Type I borosilicate glass. Material that fails any stage is not released, and the certificate published for a lot is the certificate generated for that specific synthesis – never a representative or historical document carried over from an earlier batch.

Laboratories evaluating FOXO4-DRI for the first time frequently ask for the raw analytical files rather than the summary certificate. Chromatograms, mass spectra and, where applicable, net peptide content data can be requested for any lot; our support team answers analytical questions directly rather than through a ticket queue. Institutional purchasing, repeat supply for multi-month studies and quotations for multiple strengths are handled the same way.

Terminology used on this page

Lyophilized: Freeze dried under vacuum. Removing water as vapour rather than liquid leaves a porous cake that dissolves quickly and is far more stable in storage than a peptide held in solution, which is why FOXO4-DRI is supplied this way rather than pre-reconstituted.
RP-HPLC purity: Reverse-phase high performance liquid chromatography separates the target sequence from synthesis-related impurities by hydrophobicity. The reported figure is the target peak area as a percentage of total integrated peak area; it is measured per lot and published on that lot’s certificate of analysis, against a release specification of ≥ 98%.
Mass spectrometry confirmation: An orthogonal identity check. Purity alone cannot distinguish the correct sequence from a co-eluting analogue of similar hydrophobicity; measuring the molecular ion against the expected ~5194 g/mol confirms that the peak being integrated is the intended molecule.
Net peptide content: The fraction of the vial mass that is peptide rather than counter-ion or residual water. It is the figure to use when converting a 14 mg fill into an exact molar stock concentration.
Research use only: The material is sold for in vitro and laboratory investigation by qualified personnel. It is not a medicine, supplement, food or cosmetic, carries no approval for human or veterinary administration, and must be handled under the purchasing institution’s own safety procedures.

Literature and further reading

The characterisations summarised above are drawn from peer reviewed in vitro and preclinical publications indexed in PubMed and from the corresponding entries in ChEMBL, PubChem and UniProt. Searching the compound name “FOXO4-DRI” in those databases returns the primary sources for the mechanism and application notes on this page. PrimeGen Co. does not publish clinical data and makes no therapeutic claim for this or any other catalogue item.

For laboratory research use only. Not for human or veterinary use. Not a drug, supplement, food or cosmetic. Read our research use policy before ordering.

Resource

Supplied by PrimeGen Co. within the Research Peptides category alongside related reference materials including Tesofensine 500 mcg × 30, 5-Amino-1MQ 50 mg × 30, and VIP 5 mg. FOXO4-DRI is catalogued under Research Peptides and Longevity & Cellular Research. Each lot ships with third-party certificate of analysis documentation – how to read a certificate of analysis explains each line of that report, and what HPLC purity measures covers the chromatogram behind the purity figure. Material is released against our quality control process, and is dispatched from southern Virginia – see shipping information and the FAQ before ordering. For laboratory research use only. Not for human or veterinary consumption..

FOXO4-DRI 14 mg

FOXO4-DRI 14 mg

Key facts

Laboratory specifications

Storage & handling

Certificate of analysis

Scientific overview

Mechanism of action

Areas of scientific investigation